Cellular signalling as a target in cancer chemotherapy. Phospholipid analogues as inhibitors of mitogenic signal transduction

Advances in Enzyme Regulation

Volumn 36, Issue , 1996, Pages 385-407

  Grunicke, Hans H ^a   Maly, Karl ^a   Überall, Florian ^a   Schubert, Christian ^a   Kindler, Elisabeth ^a   Stekar, Juri ^b   Brachwitz, Hans ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b ASTA MEDICA AG   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIPORTER; CALCIUM; DIACYLGLYCEROL; DRUG DERIVATIVE; ENZYME INHIBITOR; HEXADECYLPHOSPHOSERINE; INOSITOL 1,4,5 TRISPHOSPHATE; MILTEFOSINE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PHOSPHOLIPID; PHOSPHOLIPID DERIVATIVE; PHOSPHORYLCHOLINE; PHOSPHOSERINE; PROTEIN KINASE C; THROMBIN;

CALCIUM TRANSPORT; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; CONFERENCE PAPER; DRUG EFFECT; ENZYME INHIBITION; GROWTH INHIBITION; MEMBRANE DAMAGE; METABOLISM; MITOGENESIS; NEOPLASM; SIGNAL TRANSDUCTION;

EID: 0030445409     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/0065-2571(95)00015-1     Document Type: Conference Paper

References (100)

1. S. A. AARONSON, Growth factors and cancer, Science 254, 1146-1153 (1991).
2. G. L. NICOLSON, Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis, Exptl. Cell. Res. 204, 171-180 (1993).
3. J. M. BISHOP, Molecular themes in oncogenesis, Cell 64, 235-248 (1991).
4. L. C. LANTLEY, K. R. AUGER, C. CARPENTER, B. DUCKWORTH, A. BRAZIANI, R. KAPELLER and S. SOLTOFF, Oncogenes and signal transduction, Cell 64, 281-302 (1991).
5. V. G. BRUNTON and P. WORKMAN, Cell-signaling targets for antitumor drug development, Cancer Chemother. Pharmacol. 32, 1-19 (1993).
6. G. POWIS, The potential for molecular oncology to define new drug targets, pp. 1-29 in New Molecular Targets for Cancer Chemotherapy. (P. WORKMAN and D. J. KERR, eds.), Boca Raton L., CRC Press (1994).
7. A. LEVITZKI, Signal-transduction therapy. A novel approach to disease management, Eur. J. Biochem. 226, 1-13 (1994).
8. K. SZEPESHAZI, A. V. SCHALLY, R. Z. CAI, S. RADULOVIC, S. MILOVANOVIC and B. SZOKE, Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters, Cancer Res. 51, 5980-5986 (1991).
9. K. SZEPESHAZI, A. V. SCHALLY, G. HALMOS, K. GROOT and S. RADULOVIC, Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095, J. Natl. Cancer. Inst. 84, 1915-1922 (1992).
10. S. MILOVANOVIC, S. RADULOVIC, K. GROOT and A. V. SCHALLY, Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160, Prostate 20, 269-280 (1992).
11. J. P. ARMAND and E. CVITKOVIC, Suramin: A new therapeutic concept, Eur. J. Cancer 26, 417-419 (1990).
12. C. A. STEIN, R. V. LAROCCA, R. THOMAS, N. McATEE and C. E. MYERS, Suramin: An anticancer drug with a unique mechanism of action, J. Clin. Oncol. 7, 499-508 (1989).
13. M. A. EISENBERGER, L. M. REYNO, D. I. JODRELL, V. J. SINIBALDI, K. H. TKACZUK, R. SRIDHARA, E. G. ZUHOWSKI, M. H. LOWITT, S. C. JACOBS and M. J. EGORIN, Suramin, an active drug for prostate cancer: interim observations in a phase I trial, J. Natl. Cancer Inst. 85, 611-621 (1993).
14. M. A. EISENBERGER and J. A. FONTANA, Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone refractory breast cancer, J. Natl. Cancer Inst. 84, 3-5 (1992).
15. C. R. DIVGI, S. WELT, M. KRIS, F. X. REAL, S. D. YEH, R. GRALLA, B. MERCHANT, S. SCHWEIGHAR, M. UNGER and S. M. LARSON, Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma, J. Natl. Cancer Inst. 83, 97-104 (1991).
16. W. WELS, I. M. HARWERTH, M. MUELLER, B. GRONER and N. E. HYNES, Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor, Cancer Res. 52, 6310-6317 (1992).
17. A. LEVITZKI, Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction, FASEB J. 6, 3275-3282 (1992).
18. P. WORKMAN, V. G. BRUNTON and D. J. ROBINS, Discovery and design of inhibitors of oncogenic tyrosine kinases, pp. 55-70 in New Approaches in Cancer Pharmacology: Drug Design and Development (P. WORKMAN, ed.) Springer, Berlin (1994).
19. E. BUCHDUNGER, U. TRINKS, H. METT, U. REGENASS, M. MULLER, T. MEYER, E. McGLYNN, L. A. PINNA, P. TRAXLER and N. B. LYDON, 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity, Proc. Natl. Acad. Sci. U.S.A 91, 2334-2338 (1994).
20. I. L. DALE and A. GESCHER, Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cell, Int. J. Cancer 43, 158-163 (1989).
21. H. GRUNICKE and F. ÜBERALL, Protein kinase C modulation, Sem. Cancer Biol. 3, 351-360 (1992).
22. T. MEYER, U. REGENASS, D. FABBRO, E. ALTERI, J. ROSEL, M. MULLER, G. CARAVATTI and A. MATTER, A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int. J. Cancer 43, 851-856 (1989).
23. D. FABBRO, W. KUNG, S. D. COSTA, C. BORNER, U. REGENASS and U. EPPENBERGER, Involvement of protein kinase C in the growth regulation of human breast cancer cells, Cancer Treat. Res. 61, 229-248 (1992).
24. A. BASU, The potential of protein kinase C as a target for anticancer treatment, Pharmacol. Ther. 59, 257-280 (1993).
25. D. J. McNAMARA, E. M. DOBRUSIN, G. ZHU, S. J. DECKER and A. R. SALTIEL, Inhibition of binding of phospholipase C gamma 1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides, Int. J. Pept. Protein Res. 42, 240-248 (1993).
26. T. GILMER, M. RODRIGUES, S. JORDAN, R. CROSBY, K. ALLIGOOD, M. GREEN, M. KIMERY, C. WAGNER, D. KINDER and P. CHARIFSON, Peptide inhibitors of src SH3-SH2-phosphoprotein interaction, J. Biol. Chem. 269, 31711-31719 (1994).
27. T. FUNATO, T. SHITARA, T. TONE, L. JIAO, M. KASHANI-SABET and K. J. SCANLON, Suppression of H-ras-mediated transformation in NIH 3T3 cells by a ras ribozyme, Biochem. Pharmacol. 48, 1471-1475 (1994).
28. T. SAISON BEHMOARAS, B. TOCQUE, I. REY, M. CHASSIGNOL, N. T. THUONG and C. HELENE, Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation, EMBO J. 10, 1111-1118 (1991).
29. T. MUKHOPADHYAY, M. TAINSKY, A. CAVENDER and J. A. ROTH, Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA, Cancer Res. 51, 1744-1748 (1991).
30. J. B. GIBBS, A. OLIFF and N. E. KOHL, Farnesyl-transferase inhibitors: Ras research yields a potential cancer therapeutic, Cell 77, 175-178 (1994).
31. P. L. CROWELL, Z. REN, S. LIN, E. VEDEJS and M. N. GOULD, Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation, Biochem. Pharmacol. 47, 1405-1415 (1994).
32. A. VOGT, Y. QUIANS, M. A. BLASKOVICH, R. D. FOSSUM, A. D. HAMILTON and S. M. SEBTI, A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and ras processing, J. Biol. Chem. 270, 660-664 (1995).
33. J. M. TAYLOR and R. U. SIMPSON, Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse, Cancer Res. 52, 2413-2418 (1992).
34. E. C. KOHN, C. C. FELDER, W. JACOBS, K. A. HOLMES, A. DAY, R. FREER and L. A. LIOTTA, Structure function analysis of signal and growth inhibition by carboxyamidotriazole, CAI, Cancer Res. 54, 935-942 (1994).
35. E. K. KOHN, M. A. SANDEEN and L. A. LIOTTA, In vivo efficacy of a novel inhibitor of selected signal-transduction pathways including calcium, arachidonate, and inositol phosphates, Cancer Res. 52, 3208-3212 (1992).
36. G. POWIS, M. J. SEEWALD, C. GRATAS, D. MELDER, J. RIEBOW and E. J. MODEST, Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues, Cancer Res. 52, 2835-2840 (1992).
37. F. ÜBERALL, H. OBERHUBER, K. MALY, J. ZAKNUN, L. DEMUTH and H. H. GRUNICKE, Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity, Cancer Res. 51, 807-812 (1991).
38. K. MALY, F. ÜBERALL, C. SCHUBERT, E. KINDLER, J. STEKAR, H. BRACHWITZ and H. H. GRUNICKE, Interference of new alkylphospholipid analogues with mitogenic signal transduction, Anti Cancer Drug Design 10, 411-425 (1995).
39. F. W. PERELLA, C. PIANTADOSE, C. J. MARASCO and E. J. MODEST, Inhibition of phospholipase C and cell growth by ether lipid analogues of phosphatidylinositol, Proc. Am. Assoc. Cancer Res. 31, 409 (1990).
40. G. POWIS, I. A. AKSOY, D. C. MELDER, S. AKSOY, H. EICHINGER, A. H. FAUQ and A. P. KOZIKOWSKI, D-3-Deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth, Cancer Chemother. Pharmacol. 29, 95-104 (1991).
41. G. POWIS, R. BONJOUKLIAN, M. M. BERGGREN, A. GALLEGOS, R. ABRAHAM, C. ASHENDEL, L. ZALKOW, W. F. MATTER, J. DODGE and G. GRINDEY, Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase, Cancer Res. 54, 2419-2423 (1994).
42. C. J. VLAHOS, W. F. MATTER, K. Y. HUI and R. F. BROWN, A specific inhibitor of phosphatidyl-inositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248 (1994).
43. T. R. HUPP, D. W. MEEK, C. A. MIDGLEY and D. P. LANE, Activation of the cryptic DNA binding function of mutant forms of p53, Nucleic Acids Res. 21, 3167-3174 (1993).
44. Y. CHO, S. GORINA, P. D. JEFFREY and N. P. PAVLETICH, Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations, Science 265, 346-355 (1994).
45. R. ANDREESEN, M. MODOLELL, H. U. WELTZIEN and P. G. MUNDER, Alykllysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts, Immunobiol. 156, 498 (1979).
46. R. ANDREESEN, J. OSTERHOLZ, G. A. LUCKENBACH, U. COSTABEL, A. SCHULZ, V. SPETH, P. G. MUNDER and G. W. LÖHR, Tumor cytotoxicity of human macrophages after incubation with synthetic analogs of 2-lysophosphatidylcholine, J. Natl. Cancer Inst. 72, 53-59 (1984).
47. W. E. BERDEL, Membrane-interactive lipids as experimental anticancer drugs, British J. Cancer 64, 208 (1991).
48. P. HILGARD, T. KLENNER, J. STEKAR and C. UNGER, Alkylphosphocholines: a new class of membrane-active anticancer agents, Cancer Chemother. Pharmacol. 32, 90 (1993).
49. U. KIKKAWA, A. KISHIMOTO and Y. NISHIZUKA, The protein kinase C family: heterogeneity and its implications, Annu. Rev. Biochem. 58, 31-44 (1989).
50. A. AZZI, D. BOSCOBOINIK and C. HENSEY, The protein kinase C family, Eur. J. Biochem. 208, 547-557 (1992).
51. S. STABEL, Protein kinase C - an enzyme and its relatives, Cancer Biol. 5, 277-284 (1994).
52. Y. NISHIZUKA, Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C, Science 258, 607-614 (1992).
53. H. HUG and T. F. SARRE, Protein kinase C isoenzymes: divergence in signal transduction? Biochem. J. 291, 329-343 (1993).
54. A. M. CACACE, S. N. GUADAGNO, R. S. KRAUSS, D. FABBRO and I. B. WEINSTEIN, The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts, Oncogene 8, 2095-2104 (1993).
55. E. BERRA, M. T. DIAZ MECO, I. DOMINGUEZ, M. M. MUNICIO, L. SANZ, J. LOZANO, R. S. CHAPKIN and J. MOSCAT, Protein kinase C Zeta isoform is critical for mitogenic signal transduction, Cell 74, 555-563 (1993).
56. M. T. DIAZ MECO, I. DOMINGUEZ, L. SANZ, P. DENT, J. LOZANO, M. M. MUNICIO, E. BERRA, R. T. HAY, T. W. STURGILL and J. MOSCAT, zeta PKC induces phosphorylation and inactivation of I K B-alpha in vitro, EMBO J. 13, 2842-2848 (1994).
57. O. SÖZERI, K. VOLLMER, M. LIYANAGE, D. FRITH, G. KOUR, G. E. MARK and S. STABEL, Activation of the c-Raf protein kinase by protein kinase C phosphorylation, Oncogene 7, 2259-2262 (1992).
58. W. KOLCH, G. HEIDECKER, G. KOCHS, R. HUMMEL, H. VAHIDI, H. MISCHAK, G. FINKENZELLER, D. MARME and U. R. RAPP, Protein kinase Ca activates RAF-1 by direct phosphorylation, Nature 364, 249-252 (1993).
59. M. SHOJI, R. L. RANOR, E. A. M. FLEER, H. EIBL, W. R. VOGLER and J. F. KUO, Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells, Lipids 26, 145-149 (1991).
60. B. ZHENG, K. OISHI, M. SHOJI, H. EIBL, W. E. BERDEL, J. HAJDU, W. R. VOGLER and J. F. KUO, Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues, Cancer Res. 50, 3025-3031 (1990).
61. C. C. GEILEN, R. HAASE, K. BUCHNER, T. WIEDER, F. HUCHO and W. REUTTER, The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonizes phorbol ester-stimulated cell proliferation, Eur. J. Cancer 21, 1650-1653 (1991).
62. H. SALARI, P. DRYDEN, R. DAVENPORT, S. HOWARD, K. JONES and R. BITTMAN, Inhibition of PKC by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells, Biochim. Biophys. Acta 1134, 81-88 (1992).
63. 3 is not a prerequisite for growth inhibition in HL60 and K562 cells, Proc. Am. Assoc. Cancer Res. 35, 372-376 (1994).
64. S. J. COOK and M. J. WAKELAM, Phospholipases C and D in mitogenic signal transduction, Rev. Physiol. Biochem. Pharmacol. 119, 13-45 (1992).
65. S. H. EXTON, Phosphatidylcholine breakdown and signal transduction, Biochim. Biophys. Acta 1212, 26-42 (1994).
66. K. M. CONRICODE, J. L. SMITH, D. J. BURNS and J. H. EXTON, Phospholipase D activation in fibroblast membranes by the alpha and beta isoforms of protein kinase C, FEBS Lett. 342, 149-153 (1994).
67. E. MELDRUM, P. J. PARKER and A. CAROZZI, The PtdIns-PLC superfamily and signal transduction, Biochim. Biophys. Acta 1092, 49-71 (1991).
68. M. J. BERRIDGE, Inositol trisphosphate and calcium signalling, Nature 361, 315-325 (1993).
69. T. MOSMAN, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay, J. Immunol. Meth. 65, 55-63 (1983).
70. +-antiporter by a protein kinase C-independent mechanism, J. Biol. Chem. 264, 11839-11842 (1989).
71. T. K. H. VU, D. T. HUNG, V. I. WHEATON and S. R. COUGHLIN, Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation, Cell 64, 1057-1063 (1991).
72. i2 , J. Cell. Biol. 121, 91-99 (1993).
73. P. LARRODERA, M. E. CORNET, M. T. DIAZ-MECO, M. LOPEZ-BARAHONA, I. DIAZ-LAVIADA, P. H. GUDDAL, T. JOHANSEN and J. MOSCAT, Phospholipase C-mediated hydrolysis of phosphatidylcholine is an important step in PDGF-stimulated DNA synthesis, Cell 61, 1113-1120 (1990).
74. T. KONDO, H. INUI, F. KONISHI and T. INAGAMI, Phospholipase C mimics platelet-derived growth factor as a competence factor in vascular smooth muscle cells, J. Biol. Chem. 267, 23609-23616 (1992).
75. H. NAKANISHI and J. H. EXTON, Purification and characterization of the zeta isoform of protein kinase C from bovine kidney, J. Biol. Chem. 267, 16347-16354 (1992).
76. T. M. WRIGHT, L. A. RANGAN, H. S. SHIN and D. M. RABEN, Kinetic analysis of 1,2-diacylglycerol mass levels in cultured fibroblasts. Comparison of stimulation by alpha-thrombin and epidermal growth factor, J. Biol. Chem. 263, 9374-9380 (1988).
77. D. M. RABEN, M. S. PESSIN, L. A. RANGAN and T. M. WRIGHT, Kinetic and molecular species analyses of mitogen-induced increases in diglycerides: evidence for stimulated hydrolysis of phosphoinositides and phosphatidylcholine, J. Cell. Biochem. 44, 117-125 (1990).
78. M. S. PESSIN, J. J. BALDASSARE and D. M. RABENTI, Molecular species analysis of mitogen-stimulated 1,2-diglycerides in fibroblasts. Comparison of alpha-thrombin, epidermal growth factor, and platelet-derived growth factor, J. Biol. Chem. 265, 7959-7966 (1990).
79. C. LIMATOLA, D. SCHAAP, W. H. MOOLENAAR and W. J. VAN-BLITTERSWIJK, Phosphatidic acid activation of protein kinase C-zeta overexpressed in COS cells: comparison with other protein kinase C isotypes and other acidic lipids, Biochem. J. 304, 1001-1008 (1994).
80. J. STEKAR, P. HILGARD, T. KLENNER, G. NOESSNER and W. SCHUMACHER, A second generation of alkylphospholipids with high antineoplastic activity, Proc. Am. Assoc. Cancer Res. 34, 335 (1993).
81. J. STEKAR, P. HILGARD, R. VOEGELI, H. R. MAURER, J. ENGEL, B. KUTSCHER, G. NÖSSNER and W. SCHUMACHER, Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133, Cancer Chemother. Pharmacol. 32, 437-444 (1993).
82. J. STEKAR, P. HILGARD, T. KLENNER, B. KUTSCHER, G. NÖSSNER and R. VOEGELI, A novel alkylphospholipid with arsenic substituting for nitrogen (D-21805), J. Cancer Res. Clin. Oncol. 120 (Suppl): R164 (1994).
83. L. SULTZMAN, C. ELLIS, L. L. LIN, T. PAWSON and J. KNOPF, Platelet derived growth factor increases the in vivo activity of phospholipase C-gamma 1 and phospholipase C-gamma 2, Mol. Cell. Biol. 11, 2018-2025 (1991).
84. M. VALIUS and A. KAZLAUSKAS, Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal, Cell 73, 321-334 (1993).
85. E. PELES, R. B. LEVY, E. OR, A. ULLRICH and Y. YARDEN, Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma, EMBO J. 10, 2077-2086 (1991).
86. N. HAAS, H. McDANEL and A. GODWIN, Specific expression of phospholipase C-γ in human glial tumors, Proc. Am. Assoc. Cancer Res. 32, 17 (1991).
87. J. B. ROBERTSON, S. D. HURD and M. O. KOCH, Increased phospholipase C (PLC)-γ, activity in human non-small cell lung (NSCLC) and renal cell (RCC) carcinomas correlated with elevated EGF receptor levels, Proc. Am. Assoc. Cancer Res. 33, 89 (1992).
88. M. R. SMITH, S. H. RYU, P. G. SUH, S. G. RHEE and H. F. KUNG, S-phase induction and transformation of quiescent NIH 3T3 cells by microinjection of phospholipase C, Proc. Natl. Acad. Sci. U.S.A 86, 3659-3663 (1989).
89. J. S. GUTKIND, E. A. NOVOTNY, M. R. BRANN and K. C. ROBBINS, Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes, Proc. Natl. Acad. Sci. U.S.A 88, 4703-4707 (1991).
90. F. GUSOVSKY, J. E. LUEDERS, E. C. KOHN and C. C. FELDER, Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown, J. Biol. Chem. 268, 7768-7772 (1993).
91. 2+ flux but not mitogenesis, Nature 358, 678-681 (1992).
92. 2+/calmodulin-dependent protein kinases, Annu. Rev. Biochem. 61, 559-601 (1992).
93. S. G. RHEE and K. D. CHOI, Regulation of inositol phospholipid-specific phospholipase C isozymes, J. Biol. Chem. 267, 12393-12396 (1992).
94. J. H. EXTON, Phosphatidylcholine breakdown and signal transduction, Biochim. Biophys. Acta 1212, 26-42 (1994).
95. M. LISCOVITCH, Crosstalk among multiple signal-activated phospholipases, Trends Biochem. Sci. 17, 393-399 (1992).
96. W. F. SCHMIDT, K. R. HUBER, R. S. ETTINGER and R. W. NEUBERG, Antiproliferative effect of verapamil alone on brain tumor cells in vitro, Cancer Res. 48, 3617-3621 (1988).
97. J. M. TAYLOR and R. U. SIMPSON, Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse, Cancer Res. 52, 2413-2418 (1992).
98. 2+-mobilizing system to serum growth factors by Ha-ras and v-mos, Molecular and Cellular Biology 8, 4212-4216 (1988).
99. M. J. BERRIDGE and R. F. IRVINE, Inositol trisphosphate, a novel second messenger in cellular signal transduction, Nature 312, 315-321 (1984).
100. 2+-indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450 (1985).